Narpala, Sandeep

Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses

Joyce, M. G., Wheatley, A. K., Thomas, P. V., Chuang, G.-Y., Soto, C., Bailer, R. T., Druz, A., Georgiev, I. S., Gillespie, R. A., Kanekiyo, M., et al. (2016) · Cell

Influenza Virus Research Studiesvaccines and immunoinformatics approaches

Cited by 333

Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial

Casazza, J. P., Cale, E. M., Narpala, S., Yamshchikov, G. V., Coates, E. E., Hendel, C. S., Novik, L., Holman, L. A., Widge, A. T., Apte, P., et al. (2022) · Nature Medicine

Virus-based gene therapy researchHIV Research and Treatment

Cited by 91

Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial

Hamer, M. J., Houser, K. V., Hofstetter, A. R., Ortega-Villa, A. M., Lee, C., Preston, A., Augustine, B., Andrews, C., Yamshchikov, G. V., Hickman, S., et al. (2023) · The Lancet

Viral Infections and Outbreaks ResearchViral Infections and Vectors

Cited by 69

Vectored delivery of anti-SIV envelope targeting mAb via AAV8 protects rhesus macaques from repeated limiting dose intrarectal swarm SIVsmE660 challenge

Welles, H. C., Jennewein, M. F., Mason, R. D., Narpala, S., Wang, L., Cheng, C., Zhang, Y., Todd, J.-P., Lifson, J. D., Balazs, A. B., et al. (2018) · PLOS Pathogens

Virus-based gene therapy researchHIV Research and Treatment

Cited by 53